Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130809
2.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34978890
3.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33308425
4.
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Clin Infect Dis
; 70(4): 549-556, 2020 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30918967
5.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
Clin Infect Dis
; 71(5): 1255-1262, 2020 08 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31769793
6.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS
; 36(2): 185-194, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34261093
7.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS
; 35(9): 1333-1342, 2021 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33730748
8.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34648734
9.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
10.
Evaluation of the metabolism of propranolol by linear ion trap technology in mouse, rat, dog, monkey, and human cryopreserved hepatocytes.
Rapid Commun Mass Spectrom
; 23(14): 2146-50, 2009 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-19517456
11.
GSK983: a novel compound with broad-spectrum antiviral activity.
Antiviral Res
; 82(1): 1-11, 2009 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19187793
12.
Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.
Antimicrob Agents Chemother
; 47(4): 1468-71, 2003 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-12654696
13.
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Antimicrob Agents Chemother
; 46(9): 2969-76, 2002 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-12183255
14.
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.
Antimicrob Agents Chemother
; 46(8): 2365-72, 2002 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-12121906